Why Is ODYSSEY THERAPEUTICS (ODTX) Stock Up Today?
By the Top Tier Newswire AI Desk · September 17, 2026 at 10:17 AM ET · reviewed against 3 wire stories
ODYSSEY THERAPEUTICS (ODTX) is up +9.69% in the latest session. Our newswire has captured 3 stories on ODTX across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ODTX stock is up today
Odyssey Therapeutics (ODTX) surged 9.69% to $25.36 in a single session, driven by a combination of recent analyst coverage and upcoming company appearances at key industry events. The stock opened with a 1.5% gap up and reached a session high of $25.55 before closing near that level. The move reflects growing investor attention following a series of analyst actions and the company’s participation in two major healthcare conferences.
What Happened
The stock’s sharp rise comes after HC Wainwright & Co. initiated coverage on Odyssey Therapeutics with a Buy rating and a $44 price target. This was followed by JP Morgan raising its price target to $29 and maintaining an Overweight rating. Oppenheimer also reiterated its Outperform rating with a $40 price target. These analyst actions have contributed to renewed investor optimism. Additionally, Odyssey Therapeutics is scheduled to present at the Morgan Stanley 24th Annual Global Healthcare Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum. These events provide the company with a platform to highlight its autoimmune and inflammatory disease programs, including its collaboration with Evotec’s AI-driven discovery platform.
What The Data Shows
The stock’s intraday performance shows a strong upward bias, with volume reaching 0.0M shares traded so far. The stock has printed nine fresh 52-week highs on September 17, 2026, indicating sustained buying pressure. Despite the recent rally, the company remains unprofitable, with a trailing twelve-month (TTM) revenue decline of 33.5% and an EPS of -14.05. The market cap is currently $1.1B, and the stock is trading within its 52-week range of $15.10 to $29.05.
What To Watch
Investors should monitor the company’s presentations at the upcoming Morgan Stanley and Stifel conferences for further insights into its pipeline and strategic direction. The stock’s ability to sustain its recent momentum will depend on continued analyst support and positive developments in its clinical programs.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ODTX · today's session (5-min) · +3.94% vs prior close · updated 1:53 PM ETAI sentiment, last 36h · averaged over 3 stories · 56/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
17h agoSeeking AlphaBULLISH 56General
Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Odyssey Therapeutics, Inc. (ODTX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:45 AM EDTCompany ParticipantsGary Glick -...
1d agoGlobeNewswireBULLISH 56General
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) --
1d agoStockTitanBULLISH 56General
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) --
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →